Although targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy,
clinical benefit with OXPHOS inhibitors has yet to be achieved. Here we advanced IACS-…

We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of
four gynecological types plus breast. Our aims were to identify shared and unique molecular …

To date, there are no effective targeted pan-KRAS therapies. In-depth characterization of BI-3406
activity and identification of MEK inhibitors as effective combination partners provide …

The functional impact of the vast majority of cancer somatic mutations remains unknown,
representing a critical knowledge gap for implementing precision oncology. Here, we report the …

Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous
recombination (HR) deficiency (HRD) caused by mutations in BRCA1, BRCA2, and …

Abstract Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized
care in melanoma and other cancers; however, therapeutic resistance is common and …

Cancer cell lines are major model systems for mechanistic investigation and drug
development. However, protein expression data linked to high-quality DNA, RNA, and drug-screening …

Learning and memory have been closely linked to strengthening of synaptic connections
between neurons (ie, synaptic plasticity) within the dentate gyrus (DG)–CA3–CA1 trisynaptic …

Mutant RAS has remained recalcitrant to targeted therapy efforts. We demonstrate that combined
treatment with poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors and …

PARP inhibitors have been proven clinically efficacious in platinum-responsive ovarian
cancer regardless of BRCA1/2 status and in breast cancers with germline BRCA1/2 mutation. …